Be Bio has received FDA orphan drug designation and fast track status for BE-101, and has initiated a Phase I/II trial to evaluate its safety and efficacy.
Company Description
Be Bio is a biopharmaceutical company focused on developing gene therapies for hemophilia B and other rare diseases. Its lead candidate, BE-101, is designed to provide a durable replacement therapy for patients with hemophilia B by inserting the human Factor IX gene into primary human B cells.
Market
Gene Therapy
Coinvestors
Bristol Myers Squibb, Takeda Ventures, ARCH Venture Partners, Atlas Venture, RA Capital Management, Alta Partners, Longwood Fund